Stockscreener 앱 받기
7.92
4.46%
-0.37
시간 외 거래:
8.03
0.11
+1.39%
전일 마감가:
$8.29
열려 있는:
$8.45
하루 거래량:
377.08K
Relative Volume:
0.73
시가총액:
$428.99M
수익:
-
순이익/손실:
-
주가수익비율:
-1.7675
EPS:
-4.481
순현금흐름:
-
1주 성능:
-11.51%
1개월 성능:
-36.89%
6개월 성능:
-28.46%
1년 성능:
+0.00%
1일 변동 폭
$7.8722
$8.4666
1주일 범위
$7.72
$9.33
52주 변동 폭
$7.72
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
명칭
Eikon Therapeutics Inc
전화
341-777-0566
주소
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
7.92 | 428.99M | 0 | 0 | 0 | -4.481 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 개시 | BofA Securities | Buy |
| 2026-03-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-02 | 개시 | JP Morgan | Overweight |
| 2026-03-02 | 개시 | Mizuho | Outperform |
| 2026-03-02 | 개시 | Morgan Stanley | Overweight |
| 2026-02-26 | 개시 | Wedbush | Underperform |
모두보기
Eikon Therapeutics Inc 주식(EIKN)의 최신 뉴스
Eikon Therapeutics Stock: Will Upcoming ESMO Data Rekindle Investor Interest? - rttnews.com
Eikon Therapeutics, Inc. (NASDAQ:EIKN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Mizuho Upgrades Eikon Therapeutics (NASDAQ:EIKN) to "Strong-Buy" - MarketBeat
Eikon Therapeutics at Cantor conference: selective cancer drugs advance By Investing.com - Investing.com India
Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Inhibrx, Eikon rise after insider buying - tradingview.com
Eikon Therapeutics (NASDAQ:EIKN) Trading Up 6.9% After Insider Buying Activity - MarketBeat
Eikon Therapeutics (NASDAQ:EIKN) Raised to Strong-Buy at Mizuho - MarketBeat
Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ) - Seeking Alpha
Group Iv Gp Lp Column Buys 89,200 Shares of Eikon Therapeutics (NASDAQ:EIKN) Stock - MarketBeat
Open-market insider buy at Eikon Therapeutics (EIKN) - Stock Titan
Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com - Investing.com South Africa
Eikon Therapeutics Appoints CP Chang as Executive Vice President and Chief Scientific Officer - Quiver Quantitative
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer - finance.yahoo.com
Eikon Therapeutics names CP Chang as chief scientific officer - Investing.com
BlackRock Inc. Buys 962,046 Shares of Eikon Therapeutics, Inc. $EIKN - MarketBeat
$Eikon Therapeutics (EIKN.US)$ back at it again. let's do this - Moomoo
EDGAR Filing Documents for 0001193125-26-349936 - sec.gov
Eikon Therapeutics to Participate in Investor Conferences in September 2026 - The Manila Times
Eikon (EIKN) Financial Update: EPS Misses Its Estimate on the Day; After Results: The Stock Ends Up 12.46% in the Latest SessionProfit Announcement - vinanet.vn
Eikon (EIKN) Latest Quarter: Reported EPS Misses Expectations in the Latest Session; Share Move: Shares Move Higher 3.42% at the CloseProfit Cycle Analysis - careplusvn.com
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on Eikon stock - Investing.com
Eikon Therapeutics adds Merck chemistry head to advisory board By Investing.com - Investing.com Nigeria
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald - Sahm
An oncology expert will discuss PARP drugs in four cancers Aug. 20 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
EIKN Q1 2026 Earnings: Deeper-than-Expected Loss but Shares Rally 6.97%Energy Earnings Report - vinanet.vn
Morgan Stanley Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Maintains Target Price $32 - Moomoo
$Eikon Therapeutics (EIKN.US)$ - Moomoo
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com Australia
Eikon Therapeutics Updates Corporate Presentation, Files Form 8-K Under Regulation FD - kalkinemedia.com
Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside - TradingView
Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$852k - simplywall.st
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation Committee - marketscreener.com
Eikon Therapeutics, Inc. 2Q 2026: Net income $(88.4)M, EPS $(1.63) — 10-Q Summary - TradingView
Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash - Stock Titan
Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - Yahoo Finance
Eikon Therapeutics (EIKN) Earnings Date and Reports 2026 - MarketBeat
FMR LLC Expands Eikon Therapeutics Inc (EIKN) Stake Despite Post-IPO Slide - GuruFocus
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma - The Manila Times
Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced Melanoma - marketscreener.com
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. To Its Scientific Advisory Board - TradingView
Eikon Therapeutics adds Merck chemistry head to advisory board - Investing.com
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board - The Manila Times
Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board - Moomoo
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
FMR LLC reports 9.2% Eikon Therapeutics (EIKN) ownership on amended 13G - Stock Titan
Certain Warrants of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. - marketscreener.com
Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down - Stock Titan
Eikon Therapeutics Inc (EIKN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):